Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial
COVID-19 폐렴 환자에서 호흡 악화 예방을 위한 BIO101의 효능 및 안전성 테스트(COVA 연구): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
20-hydroxyecdysone
absence
accumulation
ACE2
Activation
acute respiratory distress
acute respiratory distress syndrome
adaptive
addition
administration
Airway Pressure
all-cause mortality
ALT
Alter
amenorrhea
Analysis
angiotensin
angiotensin converting enzyme
angiotensin converting enzyme 2
Angiotensin converting enzyme-2
Anti-inflammatory
anticipated
approved
ARDS
arterial oxygen saturation
AST
Asymptomatic
balance
baseline
being
Belgium
beneficiary
Bilirubin
BIO101
Biomarker
Biomarkers
birth control
blinded
Brazil
breath
Cardiomyopathy
Care
Caregivers
caused
clinical development
Clinical finding
Clinical findings
clinical picture
co-morbidities
co-morbidity
collected
Compliance
condition
condom
conducted
confirmation
Consumption
Continuous
Continuous Positive Airway Pressure
Contraception
contraceptive method
coronavirus disease
COVID-19
COVID-19 infection
COVID-19 infection symptom
COVID-19 infection symptoms
COVID-19 patient
COVID-19 patients
criteria
criterion
daily dose
Day
death
defined
Department
Deterioration
develop
diabetes
diagnosis of COVID-19
dialysis
discharge
discharged
disease
dissemination
DMC
dose
double-blind
downstream
ECMO
Effect
effective
Efficacy
Efficacy and safety
EGFR
element
eligible participant
Eligible participants
endotracheal tube
Endpoint
enzyme
etonogestrel
EudraCT
European
evaluate
event
Evidence
evidence of
exclusion criteria
expected
exploratory
extracorporeal membrane oxygenation
female
female participants
Final
FiO2
Flow
following
form
France
French
functional
Gault
Gender
healthcare
healthcare facility
heart disease
High-flow oxygen
higher risk
hospital
hospital care
Hospitalization
Hospitalized
hypersensitivity
hypertension
IBM
ICF
Imbalance
include
Inclusion
independent
indication
Infection
Inflammation
informed consent form
injection
Interim analyses
interim analysis
Intervention
intrauterine device
Intubated
Invasive mechanical ventilation
IWRS system
lactating
limit
Liver function
liver function tests
male participants
marker
Mas receptor
maximum
measure
mechanical ventilation
medical intervention
medication
medications
minute
moderate
morbidities
Moribund
Mortality
mouth
Multiorgan dysfunction
muscles
myocarditis
negative urine pregnancy test
Non-COVID-19
number
obesity
objective
observation
offer
Older
oral contraceptive
outcome
outlined
oxygen
Part
participant
partner
pathway
Pathways
patients with COVID-19
patients with SARS-CoV-2
PCR
performed
Pericarditis
Physical examination
Placebo
placebo-controlled
Pneumonia
positive airway pressure
post-intervention
post-menopausal
powder
pregnancy test
pressure
primary endpoint
proof
proportion
Proportion of participant
protocol
public health
randomised
randomised controlled trial
randomization
RAS
reached
receive
receiving
receptor
recruited
recruitment
Registered
renal
renal disease
renal insufficiency
Renin
renin angiotensin system
renin-angiotensin system
reproduction
required
resource
respiratory
Respiratory distress syndrome
Respiratory failure
Respiratory function
respiratory symptoms
restored
risk
Sample size
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV2
SARS-CoV2 spike protein
second
secondary
secondary endpoint
security
severe pneumonia
Shock
Social Security
specimen
Sperm
Spike protein
SpO2
Statistical power
status
Sterilization
Stratification
stratified
study medication
Study protocol
supplementary material
survival
suspicion
Symptom
syndrome
tachypnea
target population
tested
Testing
the primary endpoint
therapeutic
therapeutic option
tissue
Tolerability
Total
total bilirubin
Treatment
treatment arm
treatment period
Triage
Trial
Trial registration
ULN
Urine
USA
variety
vasectomy
Version
Viral load
water
website
[DOI] 10.1186/s13063-020-04998-5 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04998-5 PMC 바로가기 [Article Type] Letter